220 related articles for article (PubMed ID: 21831912)
1. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting.
Oudit GY; Bakal JA; McAlister FA; Ezekowitz JA
Eur J Heart Fail; 2011 Nov; 13(11):1211-5. PubMed ID: 21831912
[TBL] [Abstract][Full Text] [Related]
2. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care and outcomes differ for urban versus rural patients with newly diagnosed heart failure, even in a universal healthcare system.
Gamble JM; Eurich DT; Ezekowitz JA; Kaul P; Quan H; McAlister FA
Circ Heart Fail; 2011 May; 4(3):317-23. PubMed ID: 21430285
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and the risk of colorectal cancer.
van Soest EM; van Rossum LG; Dieleman JP; van Oijen MG; Siersema PD; Sturkenboom MC; Kuipers EJ
Am J Gastroenterol; 2008 Apr; 103(4):966-73. PubMed ID: 18070237
[TBL] [Abstract][Full Text] [Related]
5. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
McGowan B; Bennett K; Barry M
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor use and the antifracture efficacy of alendronate.
Abrahamsen B; Eiken P; Eastell R
Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
[TBL] [Abstract][Full Text] [Related]
7. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.
Hermos JA; Young MM; Fonda JR; Gagnon DR; Fiore LD; Lawler EV
Clin Infect Dis; 2012 Jan; 54(1):33-42. PubMed ID: 22100573
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
9. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK.
Suh DC; Hunsche E; Shin HC; Mavros P
Rheumatology (Oxford); 2008 Apr; 47(4):458-63. PubMed ID: 18263598
[TBL] [Abstract][Full Text] [Related]
10. Uses of proton pump inhibitors and serum potassium levels.
Gau JT; Heh V; Acharya U; Yang YX; Kao TC
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):865-71. PubMed ID: 19557730
[TBL] [Abstract][Full Text] [Related]
11. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
12. Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.
Hanninen M; McAlister FA; Bakal JA; van Diepen S; Ezekowitz JA
Can J Cardiol; 2013 Apr; 29(4):423-8. PubMed ID: 22985785
[TBL] [Abstract][Full Text] [Related]
13. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
Aseeri M; Schroeder T; Kramer J; Zackula R
Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653
[TBL] [Abstract][Full Text] [Related]
14. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Bajaj JS; Zadvornova Y; Heuman DM; Hafeezullah M; Hoffmann RG; Sanyal AJ; Saeian K
Am J Gastroenterol; 2009 May; 104(5):1130-4. PubMed ID: 19337238
[TBL] [Abstract][Full Text] [Related]
15. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
16. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
17. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
Ezekowitz J; McAlister FA; Humphries KH; Norris CM; Tonelli M; Ghali WA; Knudtson ML;
J Am Coll Cardiol; 2004 Oct; 44(8):1587-92. PubMed ID: 15489090
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.
de Jager CP; Wever PC; Gemen EF; van Oijen MG; van Gageldonk-Lafeber AB; Siersema PD; Kusters GC; Laheij RJ
Aliment Pharmacol Ther; 2012 Nov; 36(10):941-9. PubMed ID: 23034135
[TBL] [Abstract][Full Text] [Related]
19. Uses of proton pump inhibitors and hypomagnesemia.
Gau JT; Yang YX; Chen R; Kao TC
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):553-9. PubMed ID: 22337212
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure.
Rychli K; Richter B; Hohensinner PJ; Kariem Mahdy A; Neuhold S; Zorn G; Berger R; Mörtl D; Huber K; Pacher R; Wojta J; Niessner A; Hülsmann M
Heart; 2011 Jul; 97(14):1158-63. PubMed ID: 21572126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
